Skip to content

Advertisement

  • Research note
  • Open Access

Quality of life in mucopolysaccharidoses: construction of a specific measure using the focus group technique

BMC Research Notes201811:28

https://doi.org/10.1186/s13104-018-3157-4

  • Received: 20 September 2017
  • Accepted: 11 January 2018
  • Published:

Abstract

Objective

To describe the perceptions of patients, their caregivers, and their healthcare providers to the development of a new specific instrument for assessment of the quality of life (QoL) in patients with mucopolysaccharidoses (MPS) using a qualitative focus group (FG) design. FGs were held in two Brazilian states (Rio Grande do Sul and Rio de Janeiro).

Results

Three versions of the new instrument were developed, each for a different age group: children (age 8–12 years), adolescents (age 13–17), and adults (age ≥ 18). The FGs mostly confirmed the relevance of items. All FGs unanimously agreed on the facets: School, Happiness, Life Prospects, Religiosity, Pain, Continuity of Treatment, Trust in Treatment, Relationship with Family, Relationship with Healthcare Providers, Acceptance, and Meaning of Life. The overall concept of QoL (as proposed by the WHO—World Health Organization) and its facets apply to this patient population. However, other specific facets—particularly concerning clinical manifestations and the reality of the disease—were suggested, confirming the need for the development of a specific QoL instrument for MPS.

Keywords

  • Mucopolysaccharidoses
  • Focus group
  • Scale development
  • Disease-specific QoL measure

Introduction

The mucopolysaccharidoses (MPS) are rare genetic disorders of metabolism caused by the absence or malfunctioning of lysosomal enzymes [16]. Patients with MPS may have normal intelligence, but cognitive impairments are common. The broad range of clinical manifestations of MPS impacts on patient quality of life (QoL). Studies of Brazilian patients with different types of MPS have confirmed the severe morbidity associated with this group of disorders [712].

Assessment of QoL has been the object of increasing interest [13]. Several instruments for measurement of QoL have been studied in a variety of populations [1419]; however, there are no specific instruments for assessment of QoL in patients with MPS. A review of the literature suggests that instruments for assessment of functional status correlate positively and significantly with QoL [20].

Given the importance of taking into account the viewpoints of patients and caregivers in the planning and assessment of health care [21], there is a lack of studies and appropriate instruments for QoL evaluation in patients with MPS. Hendriksz et al. [22] conducted a literature review to survey which QoL instruments that have been used to study MPS disorders. They concluded that many of these instruments have demonstrated that QoL is negatively impacted in patients with MPS. Overall, the most affected QoL domains were pain/discomfort [23] and mobility; problems with self-care or activities of daily living were also critical factors. Also, wheelchair use, unemployment, poor endurance, and poor pulmonary function were also associated with worse QoL [2435]. The authors also noted the need for standardization and validation of QoL instruments for the different MPS disorders. This research gap suggests there is an unmet need for the development of a specific instrument for QoL assessment in patients with MPS. However, as these are very rare diseases, the construction of a specific QoL measure is particularly challenging because standard psychometric procedures (such as field testing using large samples) are impossible.

The ISPOR task force for newly developed patient-reported outcomes (PRO) instruments [36] recommended that, to ensure content validity, focus group (FGs) should be the initial qualitative step. The FG design is especially useful in the construction of culturally sensitive questionnaires or instruments for use in minority groups [37, 38].

Within this context, the present study describes the qualitative step of construction of a specific questionnaire for assessment of QoL in patients with MPS, with particular emphasis on the use of the FG method and its results.

Main text

Methods

This study is part of a larger project, composed of other stages, with the purpose of developing a specific instrument for assessment of QoL in patients with MPS. This project was designed in accordance with the methodology proposed by the WHOQOL group [19], and comprises the following stages: (1) review of the literature (originally from 1998 to 2008); (2) definition of the main facets relevant to an instrument for QoL in patients with MPS by a panel of Brazilian experts; (3) FG analysis of the expert-defined facets; (4) debriefing; (5) pilot module; (6) statistical analysis of pilot data; and (7) field testing. The present paper describes the qualitative step of FG technique (stage 3). The remaining four stages (4–7)—debriefing, administration of the pilot module, statistical analysis of pilot data, and field testing—will be described in other publications.

No descriptions of the final version of the questionnaire items will be provided in this paper; these will be the focus of a future article that will describe the field testing step.

Expert panel

Participants had been invited by e-mail. The panel comprised 15 healthcare providers that usually care for MPS patients (mainly clinical geneticists, pediatricians, and nurses), who proposed a 41-item instrument.

Focus group dynamics

Conceptually and characteristically, FG is a qualitative research method that involves a small number (ideally 5–10) of heterogeneous participants. The more heterogeneous the group is, the most diverse opinions and views will appear. The heterogeinity is one of the most important characteristics of this kind of qualitative methodology. The main purpose is to capture the opinions and viewpoints of the group (in our case, MPS patients).

Ten FGs were held following current standards for construction of PRO instruments [36]. This step took place in two Brazilian cities (Porto Alegre, state of Rio Grande do Sul, and Rio de Janeiro, state of Rio de Janeiro). Each group was meant to generate items for inclusion in the MPS QoL questionnaire, review and modify the facet definitions proposed by the expert panel, and propose additional aspects. The FGs were divided as follows: healthcare providers (HP) (group 1); caregivers or relatives of patients with MPS (group 2); children with MPS, between the ages of 8 and 12 (group 3); adolescents with MPS, between the ages of 13 and 17 (group 4); and adults (ADU) with MPS (group 5). Three versions of the instrument incorporating FG suggestions are Additional files 1, 2, 3.

All meetings were recorded and transcribed, and their content was assessed by two examiners: the lead author (MRO) and an investigator with experience in the FG technique (NSR) [39].

Subjects

Participant allocation across the FGs was carried out at the coordinating Center-Rio Grande do Sul (five FGs, one for each type of participant) and the Rio de Janeiro treatment center (also five FGs, one for each type of participant). Overall, 41 participants were included. Results are described in Table 1.
Table 1

Demographic profile of focus groups (n = 41)

 

Healthcare providers

Caregivers and relatives of MPS patients

Adults with MPS

Adolescents with MPS

Children with MPS

Number of participants

14

10

6

3

8

State of origin

10 RS, 4 RJ

6 RS, 4 RJ

3 RS, 3 RJ

2 RS, 1 RJ

6 RS, 2 RJ

MPS type

 

I = 1

II = 5

III = 2

IVa = 1

VI = 1

I = 2

II = 3

VI = 1

IV = 2

VI = 1

II = 2

IVa = 2

VI = 4

Mean age

41

42.2

24

16

11

Range

(24–58)

(21–62)

(18–33)

(15–17)

(9–13)

Sex (%)

 Male/female

2 (14.3)/12 (85.7)

3 (30)/7 (70)

3 (50)/3 (50)

2 (66.6)/1 (33.3)

6 (75)/2 (25)

Employed/student (%)

 Yes

12 (100)

7 (70)

2 (33.3)

3 (100)

8 (100)

Duration of FG

3 h 20 min

2 h 40 min

2 h 15 min

1 h 10 min

1 h 15 min

FG focus group, MPS mucopolysaccharidoses, RS Rio Grande do Sul, RJ Rio de Janeiro

Results

Among the proposed domains, the psychological domain engendered the most discussion to achieve saturation among all FGs.

Description of the focus group discussions

Physical domain

Activities of daily living: the HP FG believed it would be important to categorize these questions (with each item generating a different question) to facilitate understanding.

Functioning (will or motivation to do things): The HP group suggested that this facet include practical daily life activities, such as leisure, studies, etc. The caregiver and ADU groups suggested that the question is asked directly.

Energy (feeling lively or energetic): All FGs felt it would be important to keep this facet. Pain (usual pain): The caregiver and HP FGs believed this facet should measure pain intensity and frequency.

Sleep (sleep quality): The caregiver and HP FGs believed it would be important to assess sleep quality, as patients with MPS often experience airway obstruction, which leads to altered sleep.

Treatment (continuity and safety of treatment): All groups believed it would be important to define “treatment”.

Social domain

Family (activities and family relationship); Leisure (opportunities for and quality of leisure and recreation); School (satisfaction with school performance and relationships in school); Social relationships (quality of relationship with the community); Relationship with HP (quality of relationship with HP). All groups believed these facets should be kept.

Psychological domain

Autonomy (independence, freedom, and self-direction): All FGs, except for the children’s group, believed keeping this facet in the instrument was important.

Happiness (feeling cheerful), Dependence on parents (over protectiveness), Life prospects (plans for the future), Spirituality (influence of faith): All groups believed keeping these facets was very important.

Hope (regarding life): The ADU FG believed this facet should be excluded.

Death (thinking of death): The ADU FG and the caregiver FG diverged as to the relevance of this item. No consensus was achieved as to whether it should be kept or excluded.

Socio-economic domain

Social Security (retirement): The ADU FG suggested this facet should be excluded.

Finances (satisfaction with the financial situation), Work, Transportation (satisfaction with transportation), Knowledge of disease (information on the condition and quality of information on the condition): All groups believed these facets should be kept.

Rights (knowledge of one’s rights): The ADU FG suggested this facet should be excluded.

The originally proposed facets appear to have covered the most relevant aspects suggested (Table 2).
Table 2

Questions suggested by the adolescent MPS patient, adult MPS patient, children patient, caregiver, and healthcare providers focus groups for construction of the MPS QOL instrument, patient version

Focus group

Suggested question

Facet

Healthcare providers

Do you sleep well?

Sleep

Children with MPS

Do you wake up feeling tired or refreshed?

Caregivers

How do you feel about your sleep?

 

Healthcare providers

Do you get along well with your family?

Family

Does your family provide support when you need it?

How is your family important in your life?

Children with MPS

Do you love your family?

Are you treated well by your family?

Healthcare providers

Do you get along well with your classmates?

School

Caregivers

Do you have enough freedom to do what you like?

Autonomy

Children with MPS

Do your parents do things for you (offer lots of help)?

Caregivers

Are you satisfied with your life?

Satisfaction with life

Caregivers

Is having Social Security benefits important to you?

Social security

Healthcare providers

Would you need health insurance to supplement your treatment?

 

Adults with MPS

Do you think your health condition gets in the way of your work?

Work

Healthcare providers

Do you think your rights are respected?

Rights

 

Do you feel well-informed about your rights?

 

Caregivers

Did you receive guidance about your condition?

Knowledge of disease

 

How important is it to you to have knowledge of your condition?

 

Healthcare providers

Do you have any doubts about your condition?

 
 

What is the extent of your knowledge (or understanding) about the hereditary nature of your condition?

 

Healthcare providers

Are you satisfied with your care environment?

Treatment

Healthcare providers

Are you satisfied with your sex life?

Sex/love life

Healthcare providers

Are you satisfied with your love life?

 

Children with MPS

Do you feel cheerful?

Do you feel motivated to do things?

Energy

Children with MPS

Are you satisfied with your ability to play?

Leisure

Children with MPS

Do you feel like the others?

Appearance

Children with MPS

Do you feel that people ignore you?

Social relationships

Children with MPS

Are you satisfied with your savings? Insert $$

Finance

Among the various facets proposed, some received unanimous support across all groups (Table 3). Some of these were considered particularly important: Relationship with healthcare providers, Religiosity, Happiness, and Life prospects.
Table 3

Facets receiving unanimous support across all focus groups for construction of the MPS QOL instrument, patient version

Facet

Question

School

Are you satisfied with your school life?

Do you get along well with your teacher?

Life prospects

Do you make plans for the future?

Religiosity

Do you believe faith can help you face your problems?

Pain

Do you experience pain?

Continuity of treatment

Are you concerned about the continuity of the care you receive?

Trust in treatment

Do you trust the treatment you receive?

Family

Can you go along with your family on activities (trips, birthdays, gatherings)?

Relationship with healthcare providers

Do you get along with the professionals who take care of your health?

Acceptance

Do you take the difficulties you face in stride?

Meaning of life

Do you think your life has meaning?

Discussion

We are unaware of any studies that used the FG on patients with MPS. Furthermore, this was the first-Brazilian study to use the FG technique in children. This technique proved valid for assessment of the patient, caregiver, and HP perceptions of QoL in patients with MPS.

Overall, the facets proposed by the expert group were adequate and representative for development of an instrument to assess QoL in MPS.

Content analysis of these facets revealed that most were similar to the generic questions of the QoL assessment instrument, the WHOQOL-BREF, which covers the following aspects: overall QoL and general health perceptions; pain; dependence on medicinal substances; energy; sleep; mobility; work capacity; positive feelings; thinking, learning; self-esteem; bodily image; negative feelings, spirituality; personal relationships; sexual activity; home environment; financial resources; leisure; physical environment; and transport [19].

Facets that differed from those included in the WHOQOL instrument were associated with specific features of MPS. These included: treatment (continuity of treatment, access to treatment, trust in treatment, satisfaction); family (relationships, activities); leisure (play and sports); school (satisfaction with school life, difficulty keeping up, and relationship with teachers); relationship with HP; dependence on parents, religiosity; hope; death; affection; and knowledge of the disease.

Although MPS is a rare condition with a wide range of clinical presentations, the generic facets proposed by the WHOQOL group proved valid for this patient population [18]. However, this generic assessment did not cover the totality of elements necessary, as seen by the number of facets deemed worthy of inclusion that differed from the WHOQOL domains.

The testimonials represent the reflections and thoughts of those used to the reality of MPS. However, the viewpoints of HP on the QoL of patients with MPS stood out as somewhat different. In another study, caregivers (parents) tended to have a poorer perception of the health status of children with MPS than the children themselves, while HP’ assessments were more consistent with the perceptions reported by the children [40]. Our results were different, and this divergence may be explained by the differences among the types of MPS studied. Despite great diversity among participants and groups, there was unanimous agreement on several questions/aspects: School; Happiness; Life Prospects; Religiosity; Pain; Continuity of Treatment; Trust in Treatment; Relationship with Family; Relationship with HP; Acceptance; and Meaning of Life. However, the FGs also suggested that items could be added to the following facets: Happiness; Sleep; Family; Leisure; School; Stigmatization; Autonomy; Dependence on parents; Sex/Love Life; Social Security; Rights; Guidance/Knowledge of disease; and Work. Likewise, some FGs suggested that certain items be removed.

Particular attention should be given to the children’s group. Most Brazilian patients with MPS are children, and being able to give reliable information. Health assessment of children and adolescents, whether with generic or specific instruments, is a relevant research subject. Children as young as 5 can report reliably on concrete concepts such as pain and medication and, from the age of 9–10, can understand subjective concepts such as behavior and self-esteem [41]. Children over the age of 7 with asthma were assessed using a specific instrument and were able to understand the questions and their multiple-choice answers [41, 42].

Conclusion

By using the FG technique, we were able to capture the perceptions of patients (including in children), caregivers, and HP about QoL in MPS. The overall concept of QoL and its facets, as proposed by the WHO, apply to this patient population. However, other specific facets, mostly related to the clinical manifestations of MPS and the reality of the disease, were proposed, thus confirming the need for the development of a specific QoL instrument for this group of disorders.

Limitations

The small number of participants and inclusion restricted to patients with no mental illness might be regarded as a limitation. However, MPS is a rare group of genetic conditions, with no reliable estimates of its incidence in Brazil. Also, the next stages of development of the instrument will ascertain its ability to measure changes in health status or specific complains and to distinguish between disease stages and types, since the MPS are very heterogeneous in their clinical presentation.

Abbreviations

QoL: 

quality of life

MPS: 

mucopolysaccharidoses

WHO: 

World Health Organization

FG: 

focus group

ISPOR: 

International Society for Pharmacoeconomics and Outcomes Research

PRO: 

patient-reported outcomes

WHOQOL group: 

World Health Organization quality of life group

HP: 

healthcare providers

ADU: 

adults

WHOQOL-BREF: 

World Health Organization quality of life instrument abbreviated version

Declarations

Authors’ contributions

MRO performed analysis of the qualitative data and drafted the manuscript; IS, HM, MR, and AA took part in study conception and design and drafted the manuscript; LSC and LG conducted qualitative data collection and drafted the manuscript; NSR conceived of the study and participated in its design and coordination. All authors read and approved the final manuscript.

Acknowledgements

We are thankful to the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Brazil, for the financial support provided and tor all patients, HP, parents who agreed to participate in the study.

Competing interests

The authors declare that they have no competing interests.

Availability of the data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Consent for publication

Not applicable.

Ethics approval and consent to participate

The study was approved by the Research Ethics Committees of Hospital de Clínicas de Porto Alegre (HCPA) and Universidade Federal do Rio de Janeiro (UFRJ). All patients signed an informed consent or their relatives (children). Parents/guardians gave written informed consent for children under the age of 16 to participate in the study.

Funding

Conselho Nacional de Desenvolvimento Cientiico e Tecnologico (CNPq) and Fundo de Incentivo à Pesquisa (FIPE-HCPA).

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Universidade Federal do Rio Grande do Sul, Hospital de Clinicas de Porto Alegre, Rua Ramiro Barcelos, 2350, Santa Cecília, Porto Alegre, RS, 90035-903, Brazil
(2)
Universidade Federal Fluminense, Rua Miguel de Frias, 9 Icaraí, Niterói, RJ, 24220-008, Brazil
(3)
Universidade Federal do Rio de Janeiro, Av. Pedro Calmon, 550, Cidade Universitária, Rio de Janeiro, RJ, 21941-901, Brazil
(4)
Universidade Federal da Bahia, R. Auristides, 2, Federacao, Salvador, BA, 40210-340, Brazil
(5)
Ramiro Barcelos, 2400 2º andar, Porto Alegre, RS, 90 003-035, Brazil

References

  1. Baehner F, Schmiedeskamp C, Krummenauer F, Miebach E, Bajbouj M, Whybra C, Kohlschütter A, Kampmann C, Beck M. Cumulative incidence rates of the mucopolysaccharidoses in Germany. J Inherit Metab Dis. 2005;28:1011–7.View ArticlePubMedGoogle Scholar
  2. Nelson J. Incidence of the mucopolysaccharidoses in Northern Ireland. Hum Genet. 1997;101:355–8.View ArticlePubMedGoogle Scholar
  3. Nelson J, Crowhurst J, Carey B, Greed L. Incidence of the mucopolysaccharidoses in Western Australia. Am J Med Genet A. 2003;123A:310–3.View ArticlePubMedGoogle Scholar
  4. Applegarth DA, Toone JR, Lowry RB. Incidence of inborn errors of metabolism in British Columbia, 1969–1996. Pediatrics. 2000;105:e10.View ArticlePubMedGoogle Scholar
  5. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999;281:249–54.View ArticlePubMedGoogle Scholar
  6. Poorthuis BJ, Wevers RA, Kleijer WJ, Groener JE, de Jong JG, van Weely S, Niezen-Koning KE, van Diggelen OP. The frequency of lysosomal storage diseases in The Netherlands. Hum Genet. 1999;105:151–6.View ArticlePubMedGoogle Scholar
  7. Schwartz I, Silva LR, Leistner S, Todeschini LA, Burin MG, Pina-Neto JM, Islam RM, Shah GN, Sly WS, Giugliani R. Mucopolysaccharidosis VII: clinical, biochemical and molecular investigation of a Brazilian family. Clin Genet. 2003;64:172–5.View ArticlePubMedGoogle Scholar
  8. Azevedo AC, Schwartz IV, Kalakun L, Brustolin S, Burin MG, Beheregaray AP, Leistner S, Giugliani C, Rosa M, Barrios P, et al. Clinical and biochemical study of 28 patients with mucopolysaccharidosis type VI. Clin Genet. 2004;66:208–13.View ArticlePubMedGoogle Scholar
  9. Pinto LL, Schwartz IV, Puga AC, Vieira TA, Munoz MV, Giugliani R. Prospective study of 11 Brazilian patients with mucopolysaccharidosis II. J Pediatr (Rio J). 2006;82:273–8.Google Scholar
  10. Schwartz IV, Ribeiro MG, Mota JG, Toralles MB, Correia P, Horovitz D, Santos ES, Monlleo IL, Fett-Conte AC, Sobrinho RP, et al. A clinical study of 77 patients with mucopolysaccharidosis type II. Acta Paediatr Suppl. 2007;96:63–70.View ArticleGoogle Scholar
  11. Cardoso-Santos A, Azevedo AC, Fagondes S, Burin MG, Giugliani R, Schwartz IV. Mucopolysaccharidosis type VI (Maroteaux–Lamy syndrome): assessment of joint mobility and grip and pinch strength. J Pediatr (Rio J). 2008;84:130–5.View ArticleGoogle Scholar
  12. Vieira T, Schwartz I, Muñoz V, Pinto L, Steiner C, Ribeiro M, Boy R, Ferraz V, de Paula A, Kim C, et al. Mucopolysaccharidoses in Brazil: what happens from birth to biochemical diagnosis? Am J Med Genet Part A. 2008;146A:1741–7.View ArticlePubMedGoogle Scholar
  13. Leplege A, Hunt S. The problem of quality of life in medicine. JAMA. 1997;278:47–50.View ArticlePubMedGoogle Scholar
  14. Jenkinson C, Coulter A, Wright L. Short form 36 (SF36) health survey questionnaire: normative data for adults of working age. BMJ. 1993;306:1437–40.View ArticlePubMedPubMed CentralGoogle Scholar
  15. Jenkinson C, Chandola T, Coulter A, Bruster S. An assessment of the construct validity of the SF-12 summary scores across ethnic groups. J Public Health Med. 2001;23:187–94.View ArticlePubMedGoogle Scholar
  16. Hurst NP, Kind P, Ruta D, Hunter M, Stubbings A. Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Br J Rheumatol. 1997;36:551–9.View ArticlePubMedGoogle Scholar
  17. Skevington SM, Lotfy M, O’Connell KA, Group W. The World Health Organization’s WHOQOL-BREF quality of life assessment: psychometric properties and results of the international field trial. A report from the WHOQOL group. Qual Life Res. 2004;13:299–310.View ArticlePubMedGoogle Scholar
  18. The WHOQOL Group. The World Health Organization Quality of Life assessment (WHOQOL): position paper from the World Health Organization. Soc Sci Med. 1995;41:1403–9.View ArticleGoogle Scholar
  19. The WHOQOL group. Development of the World Health Organization WHOQOL-BREF quality of life assessment. Psychol Med. 1998;28:551–8.View ArticleGoogle Scholar
  20. Scattolin FA, Diogo MJ, Colombo RC. Correlation between instruments for measuring health-related quality of life and functional independence in elderly with heart failure. Cad Saude Publica. 2007;23:2705–15.View ArticlePubMedGoogle Scholar
  21. Coman DJ, Hayes IM, Collins V, Sahhar M, Wraith JE, Delatycki MB. Enzyme replacement therapy for mucopolysaccharidoses: opinions of patients and families. J Pediatr. 2008;152:723–7.View ArticlePubMedGoogle Scholar
  22. Hendriksz CJ, Berger KI, Lampe C, Kircher SG, Orchard PJ, Southall R, Long S, Sande S, Gold JI. Health-related quality of life in mucopolysaccharidosis: looking beyond biomedical issues. Orphanet J Rare Dis. 2016;11:119.View ArticlePubMedPubMed CentralGoogle Scholar
  23. Brands MM, Güngör D, van den Hout JM, Karstens FP, Oussoren E, Plug I, Boelens JJ, van Hasselt PM, Hollak CE, Mulder MF, et al. Pain: a prevalent feature in patients with mucopolysaccharidosis. Results of a cross-sectional national survey. J Inherit Metab Dis. 2015;38:323–31.View ArticlePubMedGoogle Scholar
  24. Harmatz P, Mengel KE, Giugliani R, Valayannopoulos V, Lin SP, Parini R, Guffon N, Burton BK, Hendriksz CJ, Mitchell J, et al. The Morquio A Clinical Assessment Program: baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjects. Mol Genet Metab. 2013;109:54–61.View ArticlePubMedGoogle Scholar
  25. Kunin-Batson AS, Shapiro EG, Rudser KD, Lavery CA, Bjoraker KJ, Jones SA, Wynn RF, Vellodi A, Tolar J, Orchard PJ, Wraith JE. Long-term cognitive and functional outcomes in children with mucopolysaccharidosis (MPS)-IH (Hurler syndrome) treated with hematopoietic cell transplantation. JIMD Rep. 2016;29:95–102.View ArticlePubMedPubMed CentralGoogle Scholar
  26. Bjoraker KJ, Delaney K, Peters C, Krivit W, Shapiro EG. Long-term outcomes of adaptive functions for children with mucopolysaccharidosis I (Hurler syndrome) treated with hematopoietic stem cell transplantation. J Dev Behav Pediatr. 2006;27:290–6.View ArticlePubMedGoogle Scholar
  27. Marucha J, Jurecka A, Syczewska M, Różdżyńska-Świątkowska A, Tylki-Szymańska A. Restricted joint range of motion in patients with MPS II: correlation with height, age and functional status. Acta Paediatr. 2012;101:e183–8.View ArticlePubMedGoogle Scholar
  28. Raluy-Callado M, Chen WH, Whiteman DA, Fang J, Wiklund I. The impact of Hunter syndrome (mucopolysaccharidosis type II) on health-related quality of life. Orphanet J Rare Dis. 2013;8:101.View ArticlePubMedPubMed CentralGoogle Scholar
  29. Needham M, Packman W, Quinn N, Rappoport M, Aoki C, Bostrom A, Cordova M, Macias S, Morgan C, Packman S. Health-related quality of life in patients with MPS II. J Genet Couns. 2015;24:635–44.View ArticlePubMedGoogle Scholar
  30. Needham M, Packman W, Rappoport M, Quinn N, Cordova M, Macias S, Morgan C, Packman S. MPS II: adaptive behavior of patients and impact on the family system. J Genet Couns. 2014;23:330–8.View ArticlePubMedGoogle Scholar
  31. Shapiro EG, Rudser K, Ahmed A, Steiner RD, Delaney KA, Yund B, King K, Kunin-Batson A, Eisengart J, Whitley CB. A longitudinal study of emotional adjustment, quality of life and adaptive function in attenuated MPS II. Mol Genet Metab Rep. 2016;7:32–9.View ArticlePubMedPubMed CentralGoogle Scholar
  32. Montaño AM, Tomatsu S, Gottesman GS, Smith M, Orii T. International Morquio A Registry: clinical manifestation and natural course of Morquio A disease. J Inherit Metab Dis. 2007;30:165–74.View ArticlePubMedGoogle Scholar
  33. Hendriksz CJ, Lavery C, Coker M, Ucar SK, Jain M, Bell L, Lampe C. Burden of disease in patients with Morquio A syndrome: results from an international patient-reported outcomes survey. Orphanet J Rare Dis. 2014;9:32.View ArticlePubMedPubMed CentralGoogle Scholar
  34. Lampe C, Jain M, Olaye A, Meesen B, Decker C, Mengel E. Relationship between patient-reported outcomes and clinical outcomes in patients with Morquio A syndrome. J Inborn Error Metab Screen. 2015;3:1–835.View ArticleGoogle Scholar
  35. Ali N, Cagle S. Psychological health in adults with morquio syndrome. JIMD Rep. 2015;20:87–93.View ArticlePubMedPubMed CentralGoogle Scholar
  36. Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E, Ring L. Content validity—establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1—eliciting concepts for a new PRO instrument. Value Health. 2011;14:967–77.View ArticlePubMedGoogle Scholar
  37. Víctora CG, Knauth DR, Hassen MN. Pesquisa qualitativa em saúde. In: Técnicas de pesquisa-grupo focal. Porto Alegre: Tomo Editorial; 2000. p. 65–7.Google Scholar
  38. Brooker J, Burney S, Fletcher J, Dally M. A qualitative exploration of quality of life among individuals diagnosed with an acoustic neuroma. Br J Health Psychol. 2009;14:563–78.View ArticlePubMedGoogle Scholar
  39. Fleck MP, Borges ZN, Bolognesi G, da Rocha NS. Development of WHOQOL spirituality, religiousness and personal beliefs module. Rev Saude Publica. 2003;37:446–55.View ArticlePubMedGoogle Scholar
  40. Landgraf J, Abetz L. Measuring health outcomes in pediatric populations: issues in psychometrics and applications. In: Spilker B, editor. Quality of life and pharmacoeconomics in clinical trials. Philadelphia: Lippincott-Raven Publishers; 1996. p. 793–802.Google Scholar
  41. Juniper EF, Guyatt GH, Feeny DH, Griffith LE, Ferrie PJ. Minimum skills required by children to complete health-related quality of life instruments for asthma: comparison of measurement properties. Eur Respir J. 1997;10:2285–94.View ArticlePubMedGoogle Scholar
  42. Sarria EE, Rosa RC, Fischer GB, Hirakata VN, Rocha NS, Mattiello R. Field-test validation of the Brazilian version of the Paediatric Asthma Quality of Life Questionnaire. J Bras Pneumol. 2010;36:417–24.View ArticlePubMedGoogle Scholar

Copyright

Advertisement